Notice on Convening the 2025 Annual General Meeting
Filed with SSE · · 7 pages · Chinese
Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. on 6ix
Earlier from Zhangzhou Pientzehuang Pharmaceutical
- Announcement on Progress in Investing in the Regenerative Medicine Fund
- Announcement on Completion of Implementation of Controlling Shareholder's Share Increase Plan and Results
- Announcement on Change of Securities Affairs Representative
- Announcement on Convening Performance Briefing for 2025 and Q1 2026
- Announcement on Receiving the "Imported Medicinal Materials Approval Document"
Later from Zhangzhou Pientzehuang Pharmaceutical
- Announcement on Completion of First Participant Enrollment in the Phase III Clinical Trial of Changji’an Capsules
- Announcement on Resolutions of the 2025 Annual General Meeting
- Announcement on Abnormal Fluctuations in Stock Trading
- Announcement on Implementation of Dividend Distribution for 2025
- Announcement on Departure of Directors and Senior Management Members
Follow Zhangzhou Pientzehuang Pharmaceutical into a list and get an email when it puts out news.
Follow Zhangzhou Pientzehuang Pharmaceutical